Bajaj Healthcare Ltd files Q1 FY2026 financial results
The company submitted its quarterly financial results for the period ended 30 June 2026, filed with BSE on 20 July 2026.
What Bajaj Healthcare Ltd announced
Bajaj Healthcare Ltd (BSE: 539872) submitted its financial results for the quarter ended 30 June 2026. The filing was made on 20 July 2026 and is available as a PDF on the BSE corporate filing portal. The announcement itself contains no quantitative details such as revenue, profit, or earnings per share; it merely informs the market that the results have been filed.
Filing details
- Filing date: 20 July 2026, 14:23:37 UTC
- Regulatory platform: Bombay Stock Exchange (BSE)
- Document reference: cb802222-264a-4cef-883a-bc449c191310.pdf
- Period covered: Quarter ended 30 June 2026 (first quarter of FY2026‑27)
Investors can download the PDF from the BSE website to review the complete set of financial statements, notes, and management discussion.
Key facts at a glance
| Detail | Value |
|---|---|
| Company | Bajaj Healthcare Ltd |
| BSE ticker | 539872 |
| Filing date | 20 July 2026 |
| Reporting period | Quarter ended 30 June 2026 |
| Document link (PDF) | cb802222-264a-4cef-883a-bc449c191310.pdf |
| Source | BSE corporate filing portal |
Why this matters for investors
The filing confirms that Bajaj Healthcare has complied with its statutory reporting obligations for the first quarter of FY2026‑27. While the announcement does not reveal the underlying numbers, the availability of the detailed PDF allows shareholders and analysts to assess the company's performance, cash flow position, and any changes in working capital. The timing of the filing—approximately three weeks after quarter‑end—is consistent with typical reporting cycles for listed Indian companies.
Conclusion
Bajaj Healthcare Ltd has formally disclosed its Q1 FY2026 results through a BSE filing on 20 July 2026. The announcement itself is brief and does not contain financial metrics; interested parties should refer to the attached PDF for the complete set of figures and commentary. No further regulatory actions or shareholder approvals are indicated in the filing.
Frequently asked questions
Related stocks
Source filing: view original